Research
Hormonal
Patients treated with semaglutide experienced a greater improvement in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) compared to placebo, with an estimated treatment difference of 7.8 points (P < .001).
Semaglutide may be an effective treatment option for improving heart failure symptoms in obese patients.
StrongSupportsmedium confidence
At 52 weeks, the KCCQ-CSS improved from baseline in both groups, but to a greater extent in patients treated with semaglutide: 16.6 vs. 8.7 points [estimated treatment difference (ETD), 7.8 points; 95% confidence interval (CI), 4.8-10.9;P < .001].
Why this rating
The study is a large, double-blind, placebo-controlled trial.
Source
Moving a STEP forward in the treatment of patients with obesity and heart failure with preserved ejection fraction
Giovanna Liuzzo et al. · European Heart Journal · 2023
rct · n=529
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →